877876-70-5

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-3-(4'-bromophenyl)-3-hydroxypropanenitrile is used as an intermediate in the pharmaceutical industry for the synthesis of various pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, (S)-3-(4'-bromophenyl)-3-hydroxypropanenitrile serves as a key intermediate in the production of agrochemicals, such as pesticides and herbicides, due to its ability to be incorporated into complex molecular structures.
Used in Organic Compounds Synthesis:
(S)-3-(4'-bromophenyl)-3-hydroxypropanenitrile is also utilized as a building block for the production of various organic compounds, including chiral intermediates and fine chemicals. Its versatility in chemical reactions allows for the creation of a wide range of specialty chemicals with specific applications.
Used in Medicinal Chemistry and Pharmaceutical Research:
(S)-3-(4'-bromophenyl)-3-hydroxypropanenitrile holds potential applications in the field of medicinal chemistry and pharmaceutical research. Its chiral nature and structural features make it an attractive candidate for the development of novel bioactive molecules with potential therapeutic properties.

Upstream product

• 4592-94-3 3-(4-bromophenyl)-3-oxopropanenitrile 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 1122-91-4 4-bromo-benzaldehyde 
• 75-05-8 acetonitrile 

Relevant academic research and scientific papers

Direct Catalytic Asymmetric Addition of Alkylnitriles to Aldehydes with Designed Nickel–Carbene Complexes

A direct catalytic asymmetric addition of acetonitrile to aldehydes that realizes over 90 % ee is the ultimate challenge in alkylnitrile addition chemistry. Herein, we report achieving high enantioselectivity by the strategic use of a sterically demanding NiII pincer carbene complex, which afforded highly enantioenriched β-hydroxynitriles. This highly atom-economical process paves the way for exploiting inexpensive acetonitrile as a promising C2 building block in a practical synthetic toolbox for asymmetric catalysis.

Extreme halophilic alcohol dehydrogenase mediated highly efficient syntheses of enantiopure aromatic alcohols

Enzymatic synthesis of enantiopure aromatic secondary alcohols (including substituted, hetero-aromatic and bicyclic structures) was carried out using halophilic alcohol dehydrogenase ADH2 from Haloferax volcanii (HvADH2). This enzyme showed an unprecedented substrate scope and absolute enatioselectivity. The cofactor NADPH was used catalytically and regenerated in situ by the biocatalyst, in the presence of 5% ethanol. The efficiency of HvADH2 for the conversion of aromatic ketones was markedly influenced by the steric and electronic factors as well as the solubility of ketones in the reaction medium. Furthermore, carbonyl stretching band frequencies ν (CO) have been measured for different ketones to understand the effect of electron withdrawing or donating properties of the ketone substituents on the reaction rate catalyzed by HvADH2. Good correlation was observed between ν (CO) of methyl aryl-ketones and the reaction rate catalyzed by HvADH2. The enzyme catalyzed the reductions of ketone substrates on the preparative scale, demonstrating that HvADH2 would be a valuable biocatalyst for the preparation of chiral aromatic alcohols of pharmaceutical interest.

Preparative access to medicinal chemistry related chiral alcohols using carbonyl reductase technology

Libraries of highly enantioenriched secondary alcohols in both enantiomeric forms were synthesised by enzymatic reduction of their parent ketones using selectAZyme carbonyl reductase (CRED) technology. Commercially available CREDs were able to reduce a range of substrate classes efficiently and with very high enantioselectivity. Matching substrate classes to small subsets of CREDs enabled the fast development of preparative bioreductions and the rapid generation of 100-1500 mg samples of chiral alcohols in typically >95% ee and the majority in ≥99.0% ee. The conditions for small scale synthesis were then scaled up to 0.5 kg to deliver one of the chiral alcohols, (S)-1-(4-bromophenyl)-2-chloroethanol, in 99.8% ee and 91% isolated yield.

Iridium diamine catalyst for the asymmetric transfer hydrogenation of ketones

A simple and very efficient chiral aqua iridium(III) diamine complex leads to excellent enantioselectivities in the asymmetric transfer hydrogenation of various α-cyano and α-nitro ketones. The catalyst provides the ortho-substituted aromatic alcohols with especially high ee values. The diamine ligands can be used directly as chiral ligands; conversion into the corresponding sulfamide is not necessary.

CHIRAL IRIDIUM AQUA COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE HYDROXY COMPOUND BY USING THE SAME

The present invention provides a novel chiral iridium aqua complex used for asymmetric transfer hydrogenation. The present invention relates to chiral iridium aqua complex represented by the formula (1): wherein R1 and R2 are the sam

Asymmetric synthesis of both antipodes of β-hydroxy nitriles and β-Hydroxy carboxylic acids via enzymatic reduction or sequential reduction/hydrolysis

Use of isolated carbonyl reductases in the reduction of aromatic β-ketonitriles have completely eliminated the competing α-ethylation, which is often observed with whole cell biocatalysts. By choosing suitable recombinant carbonyl reductase, the reduction